Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD PhD, Elias Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, MD, Erik R. Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, PhD, Anjali S. Advani, MD

Blood (2019) 134 (Supplement_1): 1344.

https://doi.org/10.1182/blood-2019-122097

Published: 2019

Journal Articles

Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Cécile Pautas, Emmanuel Raffoux, MD, Juliette Lambert, Ollivier Legrand, MD PhD, Rebecca J Benner, Erik R. Vandendries, MD PhD, Karïn Gogat, Hervé Dombret, MD, Sylvie Castaigne, MD

Blood (2018) 132 (Supplement 1): 28.

https://doi.org/10.1182/blood-2018-99-111251

Published: 2018

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Nina Wagner-Johnston, MD, Andre Goy, MD, Maria Alma Rodriguez, MD, Christopher Ehmann, MD, Paul Hamlin, MD, John Radford, MD, Catherine Thieblemont, MD, Cheolwon Suh, MD, John Sweetenham, MD, Ying Jiang, PhD, Sharon T Sullivan, PhD, Erik R Vandendries, MD, PhD, Christian Gisselbrecht, MD

Blood (2011) 118 (21): 2718.

https://doi.org/10.1182/blood.V118.21.2718.2718

Published: 2011

Journal Articles

An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,

Michinori Ogura, Toshiki Uchida, David A MacDonald, Kiyohiko Hatake, Andrew Davies, Randeep Sangha, Michael Crump, MD, FRCPC, Catherine Thieblemont, MD, Taro Ishibashi, Steven Hua, Luisa Paccagnella, Erik R Vandendries, MD, PhD, Yukio Kobayashi, Kensei Tobinai, MD

Blood (2011) 118 (21): 3715.

https://doi.org/10.1182/blood.V118.21.3715.3715

Published: 2011

Journal Articles

Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

Andre Goy, MD, Joseph Leach, MD, W. Christopher Ehmann, MD, Kiyoshi Ando, MD, PhD, Kiyohiko Hatake, MD, PhD, Kensei Tobinai, MD, PhD, Tatyana Feldman, MD, Steven Hua, Angela DG Volkert, Erik R. Vandendries, MD, PhD, Michinori Ogura, MD, PhD

Blood (2010) 116 (21): 430.

https://doi.org/10.1182/blood.V116.21.430.430

Published: 2010

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy

Nina Wagner-Johnston, Andre Goy, MD, Tatyana Feldman, MD, Yeow Tee Goh, MD, Cheolwon Suh, MD, John William Sweetenham, MD, FRCP, Christine Powell, Sharon T. Sullivan, PhD, Erik R. Vandendries, MD, PhD, Christian Gisselbrecht, MD

Blood (2010) 116 (21): 2883.

https://doi.org/10.1182/blood.V116.21.2883.2883

Published: 2010

Journal Articles

Phase 1 Study of Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Japanese Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Kiyohiko Hatake, MD, PhD, Michinori Ogura, MD, PhD, Kiyoshi Ando, MD, PhD, Kota Tokushige, Chiho Ono, PhD, Erik R. Vandendries, MD, PhD, Kensei Tobinai, MD, PhD

Blood (2010) 116 (21): 2872.

https://doi.org/10.1182/blood.V116.21.2872.2872

Published: 2010

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

Nam H. Dang, MD, PhD, Mitchell R Smith, MD, PhD, Fritz Offner, MD, Gregor Verhoef, MD, Peter Johnson, MD, Ama Z S Rohatiner, MD, Jonathan L. Kaufman, MD, Eva Gine, M.D., Bertrand Coiffier, MD, Myron S Czuczman, MD, James Foran, MD, Simon Durrant, MD, Steven Hua, PhD, Erik R. Vandendries, MD, PhD, Luis Fayad, MD

Blood (2009) 114 (22): 584.

https://doi.org/10.1182/blood.V114.22.584.584

Published: 2009

Journal Articles

Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study

Luis Fayad, Hemant Patel, PhD, Gregor Verhoef, Mitchell R. Smith, Peter W.M. Johnson, MD, FRCP, Myron S. Czuczman, MD, Bertrand Coiffier, Georg Hess, Eva Gine, Anjali Advani, MD, Fritz Offner, MD, Erik R. Vandendries, MD, PhD, Mark Shapiro, MD, PhD, FACP, Nam H. Dang, MD, PhD

Blood (2008) 112 (11): 266.

https://doi.org/10.1182/blood.V112.11.266.266

Published: 2008

Journal Articles

Protease-Activator Receptor 4 Is Required for Maximal Thrombus Growth, but Not for Fibrin Generation in Thrombi after Laser Injury.

Erik R. Vandendries, MD-PhD, Justin R. Hamilton, PhD, Shaun R. Coughlin, MD-PhD, Barbara C. Furie, PhD, Bruce Furie, MD

Blood (2004) 104 (11): 624.

https://doi.org/10.1182/blood.V104.11.624.624

Published: 2004

NARROW

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,

Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy

Phase 1 Study of Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Japanese Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study

Protease-Activator Receptor 4 Is Required for Maximal Thrombus Growth, but Not for Fibrin Generation in Thrombi after Laser Injury.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only